Sodium Citrate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Sodium Citrate
- Sodium Citrate: From Acid-Related Gastric and Upper-Airway Conditions to Papillary Conjunctivitis
Sodium Citrate: From Acid-Related Gastric and Upper-Airway Conditions to Papillary Conjunctivitis
One-Sentence Summary
Sodium citrate is an alkalinizing agent and buffer, originally used for acid-related stomach conditions (peptic ulcer, reflux, dyspepsia) and upper-airway symptoms (common cold, pharyngitis, rhinitis). The TxGNN model predicts it may be effective for papillary conjunctivitis, but the evidence is model prediction only, with 0 clinical trials and 0 publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Peptic ulcer disease, gastroesophageal reflux disease, esophagitis, dyspepsia, pharyngitis, common cold, rhinitis, nasopharyngitis (from the knowledge graph; no approved indication text was available in the Singapore licence records) |
| Predicted New Indication | Papillary conjunctivitis |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, sodium citrate is an alkalinizing agent and buffer. It is used as an antacid for acid-related gastric conditions and appears in expectorant and cough syrups, as well as in a haemofiltration solution (as an anticoagulant/buffer) and an effervescent granule product.
The relationship between these uses and papillary conjunctivitis is not clear. The original indications are gastric acid conditions and upper-airway complaints; papillary conjunctivitis is an inflammatory eye condition. The model may be drawing on loosely related inflammatory or mucosal conditions in the knowledge graph, but the data compiled for this report do not support a plausible mechanism. The high score should therefore be treated as a hypothesis-generating signal only.
For context, other predictions for this drug are more plausible. Several (nasal cavity disease, acute laryngopharyngitis) largely overlap with existing upper-airway indications, and stomach disease and gastroduodenitis are consistent with its antacid and buffering activity. These are not the focus of this report but may be better candidates for follow-up.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Seven valid single-ingredient licences are registered. Approved indication text was not available in the records.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15513P | REGIOCIT SOLUTION FOR HAEMOFILTRATION | Solution, sterile | Not available |
| SIN03335P | XSP-BENA EXPECTORANT | Syrup | Not available |
| SIN07609P | SW-BENA PAEDIATRIC EXPECTORANT | Syrup | Not available |
| SIN03251P | HOVA EXPECTORANT | Syrup | Not available |
| SIN03526P | SEMERIN COUGH SYRUP | Syrup | Not available |
Two further licences are also valid: SW BENA-EXPECTORANT (SIN02911P, syrup) and Ural Effervescent Granules (SIN14374P, effervescent granule).
No eye-drop or ophthalmic formulation is registered, so route compatibility with a conjunctival indication has not been established.
Safety Considerations
Contraindications suggested by the knowledge graph (these are graph associations, not label text):
- Cardiovascular: hypertension, coronary artery disease, myocardial infarction, coronary thrombosis
- Renal and metabolic: impaired renal function, anuria, metabolic acidosis, hypercalcaemia, nephrocalcinosis, phosphorus metabolism disorders, rhabdomyolysis
- Endocrine: adrenal insufficiency (including Addison disease and congenital adrenal hyperplasia)
- Other: pancreatitis, benign prostatic hyperplasia, angle-closure glaucoma, ocular hypertension, haemoglobinopathy
Drug Interactions: The interaction screen returned 100 records. Examples from the 20 entries shown:
- Major: aluminium hydroxide
- Moderate: doxycycline, minocycline, tetracycline, levofloxacin, acetylsalicylic acid, iron, rosuvastatin, acalabrutinib, ephedrine, pseudoephedrine
- Minor: sulfonylureas (glipizide, glyburide, chlorpropamide, tolbutamide, tolazamide, acetohexamide), lactulose, misoprostol
Of note for an ocular indication, the graph lists angle-closure glaucoma and ocular hypertension as contraindication associations, which would need careful review.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a knowledge-graph score. There are no clinical trials or publications, and no plausible mechanism linking sodium citrate to papillary conjunctivitis. Graph-based contraindication signals involving glaucoma and ocular hypertension add further caution.
To proceed, the following is needed:
- Mechanism of action data for sodium citrate and a plausible biological rationale for conjunctival disease
- Package insert warnings and contraindications from the HSA records
- Preclinical or clinical evidence in conjunctivitis, and an ophthalmic formulation and route assessment
- Consideration of the better-supported predictions (stomach disease, gastroduodenitis) as alternative research questions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.